Annexon Is Maintained at Buy by B of A Securities
Annexon Is Maintained at Buy by B of A Securities
Fate Therapeutics Price Target Raised to $6.00/Share From $2.00 by B of A Securities
Fate Therapeutics Price Target Raised to $6.00/Share From $2.00 by B of A Securities
Fate Therapeutics Is Maintained at Underperform by B of A Securities
Fate Therapeutics Is Maintained at Underperform by B of A Securities
Express News | B of A Securities Maintains Buy on Annexon, Raises Price Target to $10
Annexon Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/28/2024 36.61% B of A Securities $7 → $10 Maintains Buy 03/27/2024 309.84% HC Wainwright & Co. $30 → $3
Top Midday Gainers
Avalo Therapeutics (AVTX) shares skyrocketed amid heavy trading Thursday after the company completed the acquisition of privately held AlmataBio and said late Wednesday it entered into a private place